Designing highly active siRNAs for therapeutic applications.
about
siRNA Versus miRNA as Therapeutics for Gene SilencingSurmounting chemoresistance by targeting the Y-box binding protein-1Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides.Preclinical and clinical development of siRNA-based therapeuticsThe membrane-associated transient receptor potential vanilloid channel is the central heat shock receptor controlling the cellular heat shock response in epithelial cellsOligonucleotide-based strategies to combat polyglutamine diseases.Efficient and targeted delivery of siRNA in vivo.An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseasesPredicting the fission yeast protein interaction network.Exosome-mediated delivery of siRNA in vitro and in vivo.Computational prediction of efficient splice sites for trans-splicing ribozymes.Engineering Duplex RNAs for Challenging Targets: Recognition of GGGGCC/CCCCGG Repeats at the ALS/FTD C9orf72 LocusDesign of siRNA Therapeutics from the Molecular ScaleImproved asymmetry prediction for short interfering RNAs.siRNA Treatment: "A Sword-in-the-Stone" for Acute Brain InjuriesNon-covalent assembly of meso-tetra-4-pyridyl porphine with single-stranded DNA to form nano-sized complexes with hydrophobicity-dependent DNA release and anti-tumor activityStaying on message: design principles for controlling nonspecific responses to siRNA.Dynamic lineage analysis of embryonic morphogenesis using transgenic quail and 4D multispectral imaging.Phosphorothioate nucleotides and oligonucleotides - recent progress in synthesis and application.RNA interference for performance enhancement and detection in doping control.Small interfering ribonucleic acid design strategies for effective targeting and gene silencing.Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers.Long and short noncoding RNAs in lung cancer precision medicine: Opportunities and challenges.Therapeutic Potentials of Noncoding RNAs: Targeted Delivery of ncRNAs in Cancer Cells.Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA.Terminal Duplex Stability and Nucleotide Identity Differentially Control siRNA Loading and Activity in RNA InterferenceChitosan nanoparticle carrying small interfering RNA to platelet-derived growth factor B mRNA inhibits proliferation of smooth muscle cells in rabbit injured arteries.
P2860
Q26786876-230DB4A2-D964-4A7D-9DDF-C0C71D5EF971Q27015900-B81A38F9-0CFB-4B3E-A74E-96A86DDB38D2Q27692125-ECF98114-A870-42C1-9B21-E3DDD4D4D6DBQ28085290-8F630A5D-F29C-45B6-A33C-569A6E89D6AAQ28487063-172733FA-4805-4B3E-9ECF-F461DEB19261Q33791247-83DDE8E9-8DF0-42BB-995E-7A3C8E914419Q34149828-D8BBEBD0-30A5-4980-8C33-4FF055373525Q34187525-364BB720-6871-4ACE-8D7F-8DA362F18D76Q34271399-2703EEBC-4EF4-4CDD-A458-F898719AB5CCQ34312041-3279F248-CC38-4C41-8652-34DEB62EC7C2Q35775827-0F40E506-779B-42D4-8DCC-57ADEF362E37Q36319028-A62B71CC-06C5-4091-8780-B50469878FB7Q37111734-EAD7B590-CEC0-421C-909C-2B6213268B84Q37584772-E7EBB066-5E46-4B2D-8B59-7CE1352F67E9Q37585010-292CBF6F-062B-4B89-8EEF-9A0B790BD130Q37624060-C853C2DD-F79C-4691-B0CB-42D66CA24B51Q37809577-75208413-DA10-4A57-8974-526B2DEE49DCQ37867601-66251281-27C4-4D54-BD5A-FC546C05A028Q37933197-C56AA6F4-D537-4965-8AD8-0796C7C8D3F3Q37949928-E67910BB-5475-4DF6-9605-8F3C0075ABC0Q38014586-7515E646-BB7B-43B8-B9F2-2D2D1F50349CQ38017713-0D9F22D0-570B-4161-B8F9-67B3253DD34FQ38734500-D321C16A-258B-443C-A59B-8E3479119FA0Q38885511-0B67D02B-E2C1-4492-84EB-E7ADF8BC0D9CQ39506968-8DE66B38-23DC-4878-9580-609AE8BBB155Q41655216-475E4955-8008-4B51-ACE0-8139E48C2810Q45982870-47AD7DE6-6645-44BB-8F5B-7DAD94D5F2DB
P2860
Designing highly active siRNAs for therapeutic applications.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Designing highly active siRNAs for therapeutic applications.
@ast
Designing highly active siRNAs for therapeutic applications.
@en
Designing highly active siRNAs for therapeutic applications.
@nl
type
label
Designing highly active siRNAs for therapeutic applications.
@ast
Designing highly active siRNAs for therapeutic applications.
@en
Designing highly active siRNAs for therapeutic applications.
@nl
prefLabel
Designing highly active siRNAs for therapeutic applications.
@ast
Designing highly active siRNAs for therapeutic applications.
@en
Designing highly active siRNAs for therapeutic applications.
@nl
P2093
P2860
P1433
P1476
Designing highly active siRNAs for therapeutic applications
@en
P2093
Christina Chan
Joseph A Gredell
P2860
P304
P356
10.1111/J.1742-4658.2010.07903.X
P407
P50
P577
2010-12-01T00:00:00Z